Physiologic and metabolic safety of butyrylcholinesterase gene therapy in mice

Vaccine

Volumn 32, Issue 33, 2014, Pages 4155-4162

  Murthy, Vishakantha ^a,b   Gao, Yang ^a,b   Geng, Liyi ^a,b   LeBrasseur, Nathan K ^a,b   White, Thomas A ^b   Parks, Robin J ^c   Brimijoin, Stephen ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

Adeno associated viral vector; Butyrylcholinesterase; Cocaine addiction; Gene therapy; Helper dependent adenoviral vector; Organophosphate toxicity

Indexed keywords

ADENOVIRUS VECTOR; CHOLINESTERASE; COCAINE; GLUCOSE;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY COMPOSITION; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG SAFETY; ECHOGRAPHY; FOOD INTAKE; GENE THERAPY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HELPER DEPENDENT ADENOVIRUS; HYDROLYSIS; IN VIVO STUDY; LABORATORY DEVICE; MALE; METABOLIC PARAMETERS; METABOLIC RATE; METABOLISM; MOBILIZATION; MOUSE; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REARING; VIRAL GENE DELIVERY SYSTEM; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; BASAL METABOLIC RATE; COCAINE-RELATED DISORDERS; DEPENDOPARVOVIRUS; ENERGY METABOLISM; GENE VECTOR; GENETICS; HUMAN; MOTOR ACTIVITY; TRANSGENE;

ADENOVIRIDAE; ANIMALS; BASAL METABOLISM; BUTYRYLCHOLINESTERASE; COCAINE; COCAINE-RELATED DISORDERS; DEPENDOVIRUS; ENERGY METABOLISM; GENETIC THERAPY; GENETIC VECTORS; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MICE; MICE, INBRED BALB C; MOTOR ACTIVITY; OXYGEN CONSUMPTION; TRANSGENES;

EID: 84903444181     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.067     Document Type: Article

References (43)

1. Devlin R.J., Henry J.A. Clinical review: major consequences of illicit drug consumption. Crit Care 2008, 12(1):202. 10.1186/cc6166.
2. Giacobini E. Butyrylcholinesterase: its role in brain function. Butyrylcholinesterase, its function and inhibitors 2003, 1-19. Martin Dunitz, London, UK. E. Giacobini (Ed.).
3. Lockridge O., Duysen E., Li B. Butyrylcholinesterase function in the acetylcholinesterase knockout mouse. Butyrylcholinesterase its function and inhibitors 2003, 21-27. Martin Dunitz, London. E. Giacobini (Ed.).
4. Davies R.O., Marton A.V., Kalow W. The action of normal and atypical cholinesterase of human serum upon a series of esters of choline. Can J Biochem Physiol 1960, 38:545-551.
5. Masson P., Froment M.T., Gillon E., Nachon F., Darvesh S., Schopfer L.M. Kinetic analysis of butyrylcholinesterase-catalyzed hydrolysis of acetanilides. Biochim Biophys Acta 2007, 1774(9):1139-1147. 10.1016/j.bbapap.2007.06.004.
6. Sun H., Pang Y.P., Lockridge O., Brimijoin S. Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol 2002, 62(2):220-224.
7. Xie W., Altamirano C.V., Bartels C.F., Speirs R.J., Cashman J.R., Lockridge O. An improved cocaine hydrolase: the A328Y mutant of human butyrylcholinesterase is 4-fold more efficient. Mol Pharmacol 1999, 55:83-91.
8. Yang W., Xue L., Fang L., Chen X., Zhan C.G. Characterization of a high-activity mutant of human butyrylcholinesterase against (-)-cocaine. Chem-Biol Interact 2010, 187(1-3):148-152. 10.1016/j.cbi.2010.01.004.
9. Zheng F., Yang W., Xue L., Hou S., Liu J., Zhan C.G. Design of high-activity mutants of human butyrylcholinesterase against (-)-cocaine: structural and energetic factors affecting the catalytic efficiency. Biochemistry 2010, 49(42):9113-9119. 10.1021/bi1011628.
10. Brimijoin S., Gao Y. Cocaine hydrolase gene therapy for cocaine abuse. Future Med Chem 2012, 4(2):151-162. 10.4155/fmc.11.183.
11. Brimijoin S., Shen X., Orson F., Kosten T. Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuse. Expert Rev Vaccines 2013, 12(3):323-332. 10.1586/erv.13.1.
12. Carroll M.E., Zlebnik N.E., Anker J.J., Kosten T.R., Orson F.M., Shen X., et al. Combined Cocaine Hydrolase Gene Transfer and Anti-Cocaine Vaccine Synergistically Block Cocaine-Induced Locomotion. PLoS One 2012, 7(8):e43536. [Epub 2012 Aug 17]. 10.1371/journal.pone.0043536.
13. Gao Y., Brimijoin S. An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J Pharmacol Exp Ther 2004, 310(3):1046-1052. 10.1124/jpet.104.068122.
14. Anker J.J., Brimijoin S., Gao Y., Geng L., Zlebnik N.E., Parks R.J., et al. Cocaine hydrolase encoded in viral vector blocks the reinstatement of cocaine seeking in rats for 6 months. Biol Psychiatry 2012, 71(8):700-705. 10.1016/j.biopsych.2011.11.014.
15. Brimijoin S., Orson F., Kosten T.R., Kinsey B., Shen X.Y., White S.J., et al. Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice. Chem.-Biol. Interact. 2013, 203(1):212-216. 10.1016/j.cbi.2012.08.015.
16. Gao Y., Geng L., Orson F., Kinsey B., Kosten T.R., Shen X., et al. Effects of anti-cocaine vaccine and viral gene transfer of cocaine hydrolase in mice on cocaine toxicity including motor strength and liver damage. Chem-Biol Interact 2013, 203(1):208-211. 10.1016/j.cbi.2012.08.006.
17. Geng L., Gao Y., Chen X., Hou S., Zhan C.G., Radic Z., et al. Gene transfer of mutant mouse cholinesterase provides high lifetime expression and reduced cocaine responses with no evident toxicity. PLoS ONE 2013, 8(6):e67446. 10.1371/journal.pone.0067446.
18. Zlebnik N.E., Brimijoin S., Gao Y., Saykao A.T., Parks R.J., Carroll M.E. Long term reduction of cocaine self-administration in rats treated with adenoviral vector-delivered cocaine hydrolase: evidence for enzymatic activity. Neuropsychopharmacology 2014, May, 39(6):1538-1546. [Epub 2014 Jan 10]. 10.1038/npp.2014.3.
19. Brimijoin S., Gao Y., Anker J.J., Gliddon L.A., Lafleur D., Shah R., et al. A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats. Neuropsychopharmacology 2008, 33(11):2715-2725. 10.1038/sj.npp.1301666.
20. Saxena A., Sun W., Fedorko J.M., Koplovitz I., Doctor B.P. Prophylaxis with human serum butyrylcholinesterase protects guinea pigs exposed to multiple lethal doses of soman or VX. Biochem Pharmacol 2011, 81(1):164-169. 10.1016/j.bcp.2010.09.007.
21. Saxena A., Sun W., Luo C., Doctor B.P. Human serum butyrylcholinesterase: in vitro and in vivo stability, pharmacokinetics, and safety in mice. Chem-Biol Interact 2005, 157-158:199-203. 10.1016/j.cbi.2005.10.028.
22. Weber A., Butterweck H., Mais-Paul U., Teschner W., Lei L., Muchitsch E.M., et al. Biochemical, molecular and preclinical characterization of a double-virus-reduced human butyrylcholinesterase preparation designed for clinical use. Vox Sang 2011, 100(3):285-297. 10.1111/j.1423-0410.2010.01415.x.
23. Balazs A.B., Chen J., Hong C.M., Rao D.S., Yang L., Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012, 481(7379):81-84. nature10660 [pii], 10.1038/nature10660.
24. Kim I.H., Jozkowicz A., Piedra P.A., Oka K., Chan L. Lifetime correction of genetic deficiency in mice with a single injection of helper-dependent adenoviral vector. Proc Natl Acad Sci U S A 2001, 98(23):13282-13287. 10.1073/pnas.241506298.
25. Parks R.J., Chen L., Anton M., Sankar U., Rudnicki M.A., Graham F.L. A helper-dependent adenovirus vector system: removal of helper virus by Cre-mediated excision of the viral packaging signal. Proc Natl Acad Sci U S A 1996, 93(24):13565-13570.
26. Brimijoin S., Shen M.L., Sun H. Radiometric solvent-partitioning assay for screening cocaine hydrolases and measuring cocaine levels in milligram tissue samples. Anal Biochem 2002, 309(2):200-205.
27. Ellman G.L., Courtney K.D., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-95.
28. LeBrasseur N.K., Schelhorn T.M., Bernardo B.L., Cosgrove P.G., Loria P.M., Brown T.A. Myostatin inhibition enhances the effects of exercise on performance and metabolic outcomes in aged mice. J Gerontol A: Biol Sci Med Sci 2009, 64(9):940-948. 10.1093/gerona/glp068.
29. Izumiya Y., Hopkins T., Morris C., Sato K., Zeng L., Viereck J., et al. Fast/Glycolytic muscle fiber growth reduces fat mass and improves metabolic parameters in obese mice. Cell Metab 2008, Feb, 7(2):159-172. 10.1016/j.cmet.2007.11.003.
30. Bernardo B.L., Wachtmann T.S., Cosgrove P.G., Kuhn M., Opsahl A.C., Judkins K.M., et al. Postnatal PPARdelta activation and myostatin inhibition exert distinct yet complimentary effects on the metabolic profile of obese insulin-resistant mice. PLoS One 5(6): e11307.
31. Akasaki Y., Ouchi N., Izumiya Y., Bernardo B.L., Lebrasseur N.K., Walsh K. Glycolytic fast-twitch muscle fiber restoration counters adverse age-related changes in body composition and metabolism. Aging Cell 2013, 10.1111/acel.12153.
32. Gao Y., Atanasova E., Nan S., Pancook J.D., Watkins J.D., Brimijoin S. Gene transfer of cocaine hydrolase suppresses cardiovascular responses to cocaine in rats. Mol. Pharm 2005, 67:204-211.
33. Moralev S., Rozengart E.V. Comparative enzymology of cholinesterases 2007, LaJolla, CA.
34. Murthy V., Gao Y., Geng L., Lebrasseur N., White T., Brimijoin S. Preclinical studies on neurobehavioral and neuromuscular effects of cocaine hydrolase gene therapy in mice. J Mol Neurosci: MN 2013, 10.1007/s12031-013-0130-5.
35. Anglister L., Eichler J., Szabo M., Haesaert B., Salpeter M.M. 125I-labeled fasciculin 2: a new tool for quantitation of acetylcholinesterase densities at synaptic sites by EM-autoradiography. J Neurosci Methods 1998, 81(1-2):63-71.
36. Vogler C., Levy B., Grubb J.H., Galvin N., Tan Y., Kakkis E., et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A 2005, 102(41):14777-14782. 10.1073/pnas.0506892102.
37. Parikh K., Duysen E.G., Snow B., Jensen N.S., Manne V., Lockridge O., et al. Gene-delivered butyrylcholinesterase is prophylactic against the toxicity of chemical warfare nerve agents and organophosphorus compounds. J Pharmacol Exp Ther 2011, 337(1):92-101. jpet.110.175646 [pii].
38. Shigenaga M.K., Hagen T.M., Ames B.N. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A 1994, 91(23):10771-10778.
39. Ronn M., Lind P.M., Karlsson H., Cvek K., Berglund J., Malmberg F., et al. Quantification of total and visceral adipose tissue in fructose-fed rats using water-fat separated single echo MRI. Obesity (Silver Spring) 2013, 21(9):E388-E395. 10.1002/oby.20229.
40. Brunetti-Pierri N., Ng P. Helper-dependent adenoviral vectors for liver-directed gene therapy. Hum Mol Genet 2011, 20(R1). R7-13, ddr143 [pii], 10.1093/hmg/ddr143.
41. Raper S.E., Chirmule N., Lee F.S., Wivel N.A., Bagg A., Gao G.P., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003, 80(1-2):148-158. pii:S1096719203001690.
42. Seregin S.S., Appledorn D.M., McBride A.J., Schuldt N.J., Aldhamen Y.A., Voss T., et al. Transient pretreatment with glucocorticoid ablates innate toxicity of systemically delivered adenoviral vectors without reducing efficacy. Mol Ther 2009, 17(4):685-696. mt2008297 [pii], 10.1038/mt.2008.
43. De Rosa S.C., Lu F.X., Yu J., Perfetto S.P., Falloon J., Moser S., et al. Vaccination in humans generates broad T cell cytokine responses. J Immunol 2004, 173(9):5372-5380.